Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of "Buy" by Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been assigned an average rating of "Buy" from the ten ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $23.83.

A number of equities research analysts have commented on BNTC shares. TD Cowen started coverage on Benitec Biopharma in a report on Monday, July 7th. They set a "buy" rating on the stock. HC Wainwright reiterated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a report on Monday, May 19th. Finally, JMP Securities reiterated a "market outperform" rating and set a $20.00 target price on shares of Benitec Biopharma in a report on Thursday, May 15th.

Hedge Funds Weigh In On Benitec Biopharma

Hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. boosted its position in shares of Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock worth $448,000 after buying an additional 20,597 shares during the period. 683 Capital Management LLC acquired a new position in shares of Benitec Biopharma during the fourth quarter worth approximately $452,000. Northern Trust Corp boosted its position in shares of Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock worth $482,000 after buying an additional 13,425 shares during the period. Informed Momentum Co LLC acquired a new position in shares of Benitec Biopharma during the first quarter worth approximately $512,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Benitec Biopharma during the first quarter worth approximately $597,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Stock Performance

BNTC traded up $0.14 on Friday, hitting $11.18. 62,609 shares of the company traded hands, compared to its average volume of 58,663. The company has a 50 day moving average of $14.01 and a 200-day moving average of $12.98. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $293.48 million, a PE ratio of -7.40 and a beta of 0.37. Benitec Biopharma has a 12-month low of $7.05 and a 12-month high of $17.15.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.12. Sell-side analysts anticipate that Benitec Biopharma will post -1.48 earnings per share for the current year.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.